The stars are Aligned. ?
?
Search
Go
Browse by Topic
Sign In
Login
Login to access your membership accounts, education training and products and services.
User ID?
Password?
?Remember Me
Forgot Password
?Log In
?Create New Account 0
MENU
FDA Commissioner Vows to Eliminate Backlog of Orphan Drug Designation Requests
Posted 20 June 2017
By Michael Mezher
?
At a Senate hearing on President Donald Trump's FY2018 budget request for the US Food and Drug Administration (FDA), Commissioner Scott Gottlieb vowed to eliminate the backlog of orphan drug designation requests and said he will soon release "modern and risk-based" tools for assessing new treatments, especially for rare diseases and conditions with no effective treatments.
"Right now we have a backlog of about 200 orphan drug designation requests where we haven't responded to sponsors," Gottlieb said, noting that the agency plans to "completely eliminate" this backlog within 90 days and will strive to address all future orphan designation requests within 90 days.
Gottlieb said the agency plans to streamline its processes for reviewing orphan drug designation requests by developing an improved request template.
In addition, Gottlieb said the agency will update a number of its drug development guidance documents on targeted therapies, including "guidance on clinical trial enrichment strategies to improve efficiency and adaptive trial designs."
And, within six months, Gottlieb said the agency will issue new guidance discussing the agency's approach to evaluating targeted therapies for rare disease subsets.
"This new policy will address targeted drugs and how we can simplify the development of drugs targeted to rare disorders that are driven by genetic variations, and where diseases all have a similar genetic fingerprint even if they have a slightly different clinical expression," Gottlieb said.
Anti-Competitive Practices
During the hearing, Gottlieb also addressed questions on practices that delay generic competition, such as risk evaluation and mitigation strategy (REMS) abuse and distribution contracts that prevent generic drugmakers from obtaining drugs for bioequivalence testing.
"There is no question there are places where companies do take advantage of rules meant for one purpose as a way to gain commercial advantage," Gottlieb said, noting that he believes the agency can address the issues through administrative action.
"I don't want to be playing whack-a-mole with companies either," he added. "I want to have in place a consistent framework and a consistent set of rules that prevent these kinds of abuses."
In the near term, Gottlieb said the agency is planning to hold a public workshop to get insight on "where other people believe there are practices that could be forestalling access to generic competition [and] where branded companies might be taking advantage of certain rules."
Trump FDA Budget
Sen. Jon Tester (D-MT) asked Gottlieb how the FDA will manage to fulfill new generic drug review provisions included in the Senate's user fee reauthorization bill under the President's budget proposal, noting that the Congressional Budget Office (CBO) estimated the agency would need to hire an additional 500 full-time-equivalent employees to meet those mandates.
"I wasn't involved with the formulation of the budget. I would have to obviously make it work if the budget were passed as it was proposed," Gottlieb responded.
Sen. John Hoeven (R-ND), meanwhile, said he was "concerned that [Trump's budget] request relies on a significant increase in user fees that is not feasible and unlikely to gain congressional approval," later noting that he believes Congress will ultimately pass the previously negotiated user fees.
Hearing
Share this article:
Categories: Generic drugs, Orphan products, News, US, FDA
Tags: FY2018 Budget, Appropriations, Orphan Drug Designations, REMS, Scott Gottlieb
You must be logged in to leave a comment
Related Links
Decision on EMA Relocation Set for November, Council Agrees on Bidding Procedure
EMA Recommends New HCV, Cancer and MS Drugs for Approval
Regulatory Recon: FDA Rejects Pfizer Epogen Biosimilar Over Warned Manufacturing Site; Novartis, CSL Behring & Roche Pick Up US Approvals (23 June 2017)
Senate Health Bill Would Repeal Device Tax
?
?
Regulatory Focus Menu
Regulatory Focus Home
Regulatory News
Feature Articles
RAPS' Latest
Research and Resources
About Regulatory Focus
Advertise
Subscribe to RF Today
?
Search This Section
Go
Browse by Topics Within this Section
RF Today
Get important news and events in regulatory.
Sign up for regular emails from RAPS. We'll never share your info and you can unsubscribe any time.
?
Email
?Sign Me Up
?
Most Viewed News Articles
Regulatory Recon: ViiV, GSK Use Priority Review Voucher for 2-Drug HIV Combo; NICE Backs Opdivo for Classical Hodgkin Lymphoma (2 June 2017)
Published 02 June 2017
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. View More
FDA Approves First Generic Version of Gilead's HIV Drug Truvada
Published 09 June 2017
The US Food and Drug Administration (FDA) on Friday announced it has approved Teva Pharmaceuticals' generic version of Gilead's HIV drug Truvada (emtricitabine and tenofovir disoproxil fumarate). View More
US Supreme Court: No Six-Month Wait for Biosimilars After FDA Approval
Published 12 June 2017
The US Supreme Court on Monday ruled unanimously that biosimilar companies will not have to wait an additional six months after US Food and Drug Administration (FDA) approval before launching their new biosimilars. View More
FDA Unveils List of Reusable Devices Requiring New Validation Data
Published 08 June 2017
Following superbug outbreaks after issues with reprocessing certain medical devices, the US Food and Drug Administration (FDA) on Thursday released a list of devices that the agency will require validated instructions for use and validation data regarding cleaning, disinfection and sterilization in premarket notification submissions. View More
?
Regulatory Exchange: Latest Updates From the Community
Clinical Evaluation of Medical Devices under new EU CER
We have successfully done our own clinical evaluations in the past, but our NB has now said our evaluations are inadequate due to the new Clinical Evaluation Regulation in the EU. The main issue is t...
RE: Preparation to move from Paper to electronic (IND and NDA)
Hi Susan,
From my views, you would be best prepared to select your potential vendor when you know exactly what you WANT and NEED.
...
RE: Preparation to move from Paper to electronic (IND and NDA)
Hi Everyone
Thanks so much for the really useful feedback. I realise now that my original query wasn't as clear as I should have made it! We are not looking to create the esubmissions our...
RE: GMDN Codes
If you do not have an account with the GMDN agency, you can also search through FDA's preferred terms if you have access to GUDID. The term names and descriptions are the same as GMDN, FDA has assign...
© 2017 Regulatory Affairs Professionals Society | Online Policies | Terms of Use | Site Map | Contact RAPS | Advertise with RAPS
ShareThis Copy and Paste
